Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Accelerated epigenetic aging and DNA methylation alterations in Berardinelli-Seip congenital lipodystrophy

Qannan A., Bejaoui Y., Izadi M., Yousri NA., Razzaq A., Christiansen C.

Prospective Study on Type 2 Diabetes, published in Hum Mol Genet (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Hum Mol Genet (2023)
Reported sample size
—
Source database
Europe PMC
PMID
36715159
PMCID
PMC10196674
DOI
10.1093/hmg/ddad016
Citations
13

Abstract (original English)

Berardinelli-Seip congenital lipodystrophy type 2 (CGL2) is a very rare human genetic disorder with potential significance to the understanding of the pathobiology of aging. CGL2 patients display characteristic progeroid features and suffer from type 2 diabetes, insulin resistance and fatty liver. In this study, we profiled genome-wide DNA methylation levels in CGL2 patients with BSCL2 mutations to study epigenetic age acceleration and DNA methylation alterations. This analysis revealed significant age acceleration in blood DNA of CGL2 patients using both first- and second-generation epigenetic clocks. We also observed a shortened lifespan of Caenorhabditis elegans following knockdown of the BSCL2 homolog seip-1 on a daf-16/forkhead box, class O mutant background. DNA methylation analysis revealed significant differentially methylated sites enriched for lyase activity, kinase regulator activity, protein kinase regulator activity and kinase activator activity. We could also observe significant hypomethylation in the promoter of the dual specificity phosphatase 22 gene when comparing CGL2 patients versus controls. We conclude that in line with the observed progeroid features, CGL2 patients exhibit significant epigenetic age acceleration and DNA methylation alterations that might affect pathways/genes of potential relevance to the disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansLipodystrophyDiabetes Mellitus, Type 2GTP-Binding Protein gamma SubunitsDNA MethylationEpigenesis, GeneticAgingMutationLipodystrophy, Congenital Generalized

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research